A best evidence topic was written according to a structured protocol. The question addressed was whether on-pump beating heart coronary artery bypass (BH-ONCAB) surgery has a different outcome profile in comparison to off-pump coronary artery bypass (OPCAB). A total of 205 papers were found by systematic search of which 7 provided the largest and most recent outcome analysis comparing BH-ONCAB with OPCAB, and represented the best evidence to answer the clinical question. The authors, date, journal, study type, population, main outcome measures and results were tabulated. Reported outcome measures included mortality, stroke, myocardial infarction, renal failure, myocardial damage, change in ejection fraction, number of bypass grafts and completeness of revascularization. With the exception of one study that favoured the off-pump technique, our review did not demonstrate a statistically significant difference in terms of mortality between the groups. We did not identify a statistically significant difference in any reported morbidity outcomes. However, there was a trend towards better outcomes for the on-pump beating heart technique, despite a higher risk profile in terms of age, ejection fraction and burden of coronary disease in this group. Consistent statistically significant differences between the groups were the mean number of grafts performed and the completeness of revascularization, both of which were higher with the on-pump beating heart technique. Limitations to the current evidence include the finding that most of the current data arise from specialist off-pump surgeons or centres that would usually only carry out BH-ONCAB in the higher risk patients where the added safety of cardiopulmonary bypass is desired.
INTRODUCTION
A best evidence topic was constructed according to a structured protocol as fully described in ICVTS [1] .
CLINICAL SCENARIO
A 74-year old lady with chest pain and shortness of breath on exertion is referred for coronary artery bypass grafting (CABG). Her comorbidities include peripheral vascular disease with previous right femoral-popliteal bypass and left carotid endarterectomy. Chest radiography and subsequent chest computerized tomography reveal a heavily calcified ascending aorta. Coronary angiography demonstrates a right-dominant system and critical stenosis of the proximal left anterior descending artery, ostial diagonal and posterior descending coronary arteries. Echocardiography demonstrates moderately impaired left ventricular systolic and diastolic function and no valvular pathology. You decide that limiting aortic manipulation and avoiding cross-clamping would be essential, and contemplate whether she would most benefit from off-pump (OPCAB) or on-pump beating heart (BH-ONCAB) coronary revascularization. 
THREE-PART QUESTION

SEARCH OUTCOME
Two hundred and five articles were identified by systematic search. Of these, seven provided the best evidence to answer the clinical question [2] [3] [4] [5] [6] [7] . These are presented in Table 1 .
RESULTS
In their retrospective observational study of 104 chronic haemodialysis patients undergoing CABG (48 BH-ONCAB, 56 OPCAB), Tsai et al. [2] showed no significant difference in 30-day mortality (4.2 vs 5.4%) or stroke (1.8 vs 2.1%) between BH-ONCAB and OPCAB. The mean number of grafts performed in the BH-ONCAB group was significantly higher (3.2 ± 0.8 vs 2.4 ± 1.0; P < 0.01); however, this population also had a significantly higher coronary disease burden.
Tarakji et al. [3] conducted a prospective cohort study of 2397 patients undergoing primary or reoperative CABG (234 BH-ONCAB, 2163 OPCAB). All stroke rate (intra-and postoperative) was lower with OPCAB than BH-ONCAB (0.79 vs 1.7%).
Letsou et al. [4] conducted a retrospective observational study of 481 patients undergoing primary or reoperative CABG (84 BH-ONCAB, 397 OPCAB). All procedures began as OPCAB; however, 84 were converted to BH-ONCAB. Significantly more patients in the BH-ONCAB group had a preoperative ejection fraction (EF) below 40% (26.9 vs 18.1%; P < 0.001). Postoperatively, OPCAB and BH-ONCAB displayed similar significant improvements in EF (BH-ONCAB 6.8% vs OPCAB 5.4%; P = 0.65) when compared with preoperative findings. Overall mortality was 0.8% (4/481); however, this was not separated by study group.
In their retrospective observational study of 108 high-risk patients (51 BH-ONCAB, 57 OPCAB), Munos et al. [5] showed no significant difference in 30-day mortality (1.9 vs 3.5%), stroke (0 vs 1.7%), perioperative myocardial infarction (1.9 vs 3.5%) or completeness of revascularization (95 vs 89%) between the groups. BH-ONCAB was associated with significantly more grafts per patient than OPCAB (2.45 ± 0.8 vs 2.15 ± 0.78; P < 0.01).
Darwazah et al. [6] similarly showed no significant differences observed in 30-day mortality (8 vs 6%), stroke (3 vs 1%), myocardial infarction (13.15 vs 8%) and renal failure (8 vs 3%) between OPCAB and BH-ONCAB in their retrospective observational study of 137 patients (EF <35%; 39 BH-ONCAB, 98 OPCAB). OPCAB resulted in significantly fewer ventricular arrhythmias (4 vs 23%; P = 0.002); however, the technique was also associated with significantly fewer grafts (1.7 ± 0.7 vs 2.2 ± 0.7; P < 0.002) and less complete revascularization than BH-ONCAB (46 vs 72%; P = 0.015).
Reber et al. [7] conducted a retrospective observational study of 302 patients (117 BH-ONCAB, 185 OPCAB) using miniaturized cardiopulmonary bypass. BH-ONCAB patients were older (72.1 ± 9 vs 69.3 ± 1; P = 0.04), had a higher EuroSCORE (6.5 vs 5.4; P = 0.011) and more had moderate to severely impaired left ventricular ejection fraction (<30%) (10 vs 3%; P = 0.013). Thirty-day mortality was comparable between the groups (3.2 vs 6.2%); however, significantly more grafts per patient were performed with BH-ONCAB (2.14 ± 0.4 vs 1.7 ± 0.6; P < 0.001).
Edgerton et al. [8] conducted a retrospective observational study of 2272 patients (364 BH-ONCAB, 1908 OPCAB). BH-ONCAB patients had significantly more three-vessel disease (85.1 vs 68%; P < 0.001), lower EF (45.6 ± 12.5 vs 51.0 ± 13.1; P < 0.05) and higher projected mortality (0.037 ± 0.06 vs 0.031 ± 0.04; P < 0.05). BH-ONCAB was associated with significantly more grafts per patient (3.29 ± 1.03 vs 2.9 ± 1.13; P < 0.05) but also resulted in significantly greater hospital mortality (4.4 vs 2.3%; P = 0.04) and renal failure (9.1 vs 2.4%; P < 0.001). There were no significant differences in stroke (1.4 vs 0.8%) or myocardial infarction (0.8 vs 0.5%).
There remains on-going extensive debate regarding the comparison between on-pump cardioplegic arrested CABG and OPCAB. However, limited focus has been placed upon the technique of on-pump beating heart surgery. BH-ONCAB may be an attractive option in the appropriate patient population particularly where off-pump is technically challenging. Advantages include the avoidance of aortic cross-clamping, the absence of global myocardial ischaemia ( particularly where intraluminal shunts are used), and the haemodynamic security of cardiopulmonary bypass that may circumvent the risks of conversion.
CLINICAL BOTTOM LINE
With the exception of one study favouring OPCAB [8] , the current best evidence does not demonstrate any statistically significant mortality difference between BH-ONCAB and OPCAB. Similarly, morbidity outcomes were statistically comparable within the best available evidence. One consistent difference was that BH-ONCAB was associated with significantly more grafts per patient and more complete revascularization. However, inherent selection biases and the greater preoperative risk profile of BH-ONCAB patients should be remembered when interpreting these results.
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